DocGo (DCGO) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue was $138.7M, down 26% year-over-year due to the planned wind down of migrant-related projects, but YTD revenue rose 17% to $495.7M.

• Net income for Q3 2024 was $4.5M, nearly flat year-over-year; YTD net income surged to $21.0M from $2.1M in 2023, driven by expanded Mobile Health Services and improved cost management.

• Adjusted EBITDA for Q3 2024 increased to $17.9M, with margin rising to 12.9% from 8.9% year-over-year; YTD adjusted EBITDA up 88% to $59.2M.

• Expanded operational footprint with new hubs on the West Coast, doubled patients in care gap closure programs to over 500,000, and signed major contract expansions.

• Migrant-related programs extended longer than expected, increasing 2024 migrant-related revenue forecast, but consolidated 2024 revenue guidance remains unchanged.

Financial highlights

• Q3 2024 revenue: $138.7M (down 26% year-over-year); nine months: $495.7M (up 16.6%).

• Q3 2024 net income: $4.5M; nine months: $21.0M (up from $2.1M in 2023).

• Q3 2024 adjusted EBITDA: $17.9M; adjusted EBITDA margin: 12.9%.

• Q3 2024 adjusted gross margin: 36% (up from 29.5%); mobile health segment adjusted gross margin: 38.8%.

• Cash and equivalents at Q3 end: $108.6M, up from $85.8M in Q2 and $59M in Q1.

Outlook and guidance

• 2024 revenue guidance refined to $620–$630M, with adjusted EBITDA of $70–$75M and cash flow from operations raised to $90–$100M.

• 2025 consolidated revenue guidance set at $410–$450M, including $50M from migrant-related work, with adjusted EBITDA margin expected at 8–10%.

• Mobile Health Services revenue expected to decline further in Q4 2024 as migrant-related projects wind down, despite new project launches.

• Transportation Services expected to maintain growth in trip volumes, with average trip price stabilizing above early 2022 levels.